Premature ovarian insufficiency: the Spanish Menopause Society (AEEM) and the European Society of Gynecology (ESG) position statement
European Gynecology & Obstetrics · 22.05.2025 · 7 (1)
DOI: 10.53260/ego.257018 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Gynecology & Obstetrics, online erschienen am 22.05.2025. Verfasst von Camil Castelo-Branco und 17 weiteren Autor:innen. Die Arbeit nennt 80 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Premature ovarian insufficiency (POI) is an uncommon condition affecting 1–2% of women younger than 40, 1 in 1,000 in their thirties and 1 in 10,000 under 20 years of age. The multiple etiologies of this clinical condition can be classified as primary (chromosomal, genetic, endocrine, infectious, autoimmune) and secondary or iatrogenic (surgery, chemotherapy and/or radiotherapy). Despite important progress in genetics, most of the cases of primary POI are still classified as idiopathic. POI is defined by the association of one clinical and one biological criterion: primary or secondary amenorrhea or cycle irregularities of more than 4 months with onset before 40 years of age, and elevated follicle-stimulating hormone (FSH) on 2 assays at different times. Commonly, estradiol levels are low, and anti-Müllerian hormone (AMH) levels are almost undetectable. Initial diagnostic procedures comprise hormonal and auto-immune assessment, karyotype, FMR1 premutation screening and gene-panel study. The term ovarian insufficiency suggests that the lack of function is not necessarily definitive; therefore, it is important not to use the term premature menopause when a young patient is reporting this condition, since in some cases ovarian function may be restored spontaneously, and pregnancy may occur in about 6% of cases. In confirmed POI, hormone replacement therapy is mandatory at least up to the physiological age of the menopause onset. Management in a tertiary center is suggested.
Zitieren
APA
Castelo-Branco, C., Gasull, M. G., Mainar, L. B., Cancelo-Hidalgo, M. J., Cano, A., Arribas, E. G., Martínez, S. L., Suárez, C. L., Coto, P. L., Guevara, N. M. L. D., Pozo, I. P. D., Quereda, F., Comella, B. R., Ramagosa, C., Duarte, P. R., Chabbert-Buffet, N., Serfaty, D., & Genazzani, A. (2025). Premature ovarian insufficiency: the Spanish Menopause Society (AEEM) and the European Society of Gynecology (ESG) position statement. European Gynecology & Obstetrics, 7(1). https://doi.org/10.53260/ego.257018
Vancouver
Castelo-Branco C, Gasull MG, Mainar LB, Cancelo-Hidalgo MJ, Cano A, Arribas EG, et al. Premature ovarian insufficiency: the Spanish Menopause Society (AEEM) and the European Society of Gynecology (ESG) position statement. European Gynecology & Obstetrics. 2025;7(1). doi:10.53260/ego.257018
BibTeX
@article{CasteloBranco2025,
author = {Castelo-Branco, Camil and Gasull, Misericordia Guinot and Mainar, Laura Baquedano and Cancelo-Hidalgo, María J. and Cano, Antonio and Arribas, Elisa Gil and Martínez, Sonia Lobo and Suárez, Cristina Llaneza and Coto, Plácido Llaneza and Guevara, Nicolás Mendoza Ladrón de and Pozo, Irene Perelson del and Quereda, Francisco and Comella, Beatriz Roca and Ramagosa, Carla and Duarte, Pablo Romero and Chabbert-Buffet, Nathalie and Serfaty, David and Genazzani, Andrea},
title = {Premature ovarian insufficiency: the Spanish Menopause Society (AEEM) and the European Society of Gynecology (ESG) position statement},
journal = {European Gynecology & Obstetrics},
year = {2025},
volume = {7},
number = {1},
doi = {10.53260/ego.257018}
}
EUVIMED